EGI
TVRD

EAM Global Investors’s Tvardi Therapeutics TVRD Stock Holding History

EAM Global Investors’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-1,777
Closed -$1.17M – 152
2019
Q3 		$1.17M Buy
+1,777
New +$1.48M 0.57% 92
2018
Q4 		– Sell
-1,786
Closed -$1.54M – 168
2018
Q3 		$1.54M Buy
+1,786
New +$1.29M 0.62% 63

Other funds holding TVRD

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

EAM Global Investors's TVRD Position: Q4 2019 in Review

EAM Global Investors sold out of Tvardi Therapeutics (TVRD) in Q4 2019, closing a stake of 1,777 shares — an estimated $1.17M sold.

EAM Global Investors first reported a position in TVRD in Q3 2018 and held it in 2 quarters. The position peaked at $1.54M in Q3 2018. 151 funds tracked by Wall St. Rank hold TVRD as of Q4 2019.

  • EAM Global Investors reported no remaining Tvardi Therapeutics position as of Q4 2019 after selling out during the quarter.
  • EAM Global Investors sold 1,777 Tvardi Therapeutics shares in Q4 2019, an estimated $1.17M.
  • EAM Global Investors first reported a position in Tvardi Therapeutics in Q3 2018 and held it in 2 quarters.
  • EAM Global Investors's Tvardi Therapeutics position peaked at $1.54M in Q3 2018.
  • 151 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2019.

Based on EAM Global Investors's 13F filing for Q4 2019, filed 10 Feb 2020.